Restricted accessResearch articleFirst published online 2017-7-29
The Distinction of Amyloid-β Protein Precursor (AβPP) Ratio in Platelet Between Alzheimer’s Disease Patients and Controls: A Systematic Review and Meta-Analysis
To systematically assess the clinical significance of platelet amyloid-β protein precursor (AβPP) ratio between Alzheimer’s disease (AD) patients and controls. 14 articles were selected in this analysis by search of databases including PubMed and Web of Science up to December 2016. Random effects models were used to calculate the standardized mean difference (SMD). Subgroup analyses were used to detect the cause of heterogeneity. The result showed a significant drop in platelet AβPP ratio in AD patients compared to controls [SMD: –1.871; 95% CI: (–2.33, –1.41); p < 0.001; I2 = 88.0% ]. Subgroup analysis revealed races or the quality of studies may be the cause of high heterogeneity. This meta-analysis concluded that there is a close association between platelet AβPP ratio and AD. It is necessary to design a sizable sample study to further support that platelet AβPP ratio can be a biomarker of AD.
PalmqvistS, ZetterbergH, MattssonN, JohanssonP, MinthonL, BlennowK, OlssonM, HanssonO (2015) Detailed comparison ofamyloid PET and CSF biomarkers for identifying earlyAlzheimer disease. Neurology85, 1240–1249.
6.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
BairdAL, WestwoodS, LovestoneS (2015) Blood-based proteomic biomarkers of Alzheimer’s disease pathology. Front Neurol6, 236.
9.
ErikssonUK, PedersenNL, ReynoldsCA, HongMG, PrinceJA, GatzM, DickmanPW, BennetAM (2011) Associations of gene sequence variation and serum levels of C-reactive protein and interleukin-6 with Alzheimer’s disease and dementia. J Alzheimers Dis23, 361–369.
10.
RembachA, FauxNG, WattAD, PertileKK, RumbleRL, TrounsonBO, FowlerCJ, RobertsBR, PerezKA, LiQX, LawsSM, TaddeiK, Rainey-SmithS, RobertsonJS, VandijckM, VandersticheleH, BarnhamKJ, EllisKA, SzoekeC, MacaulayL, RoweCC, VillemagneVL, AmesD, MartinsRN, BushAI, MastersCL (2014) Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease. Alzheimers Dement10, 53–61.
11.
ZetterbergH, WilsonD, AndreassonU, MinthonL, BlennowK, RandallJ, HanssonO (2013) Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther5, 9.
12.
ZhouL, ChanKH, ChuLW, KwanJS, SongYQ, ChenLH, HoPW, ChengOY, HoJW, LamKS (2012) Plasma amyloid-beta oligomers level is a biomarker for Alzheimer’s disease diagnosis. Biochem Biophys Res Commun423, 697–702.
13.
ShiM, SuiYT, PeskindER, LiG, HwangH, DevicI, GinghinaC, EdgarJS, PanC, GoodlettDR, FurayAR, Gonzalez-CuyarLF, ZhangJ (2011) Salivary tau species are potential biomarkers of Alzheimer’s disease. J Alzheimers Dis27, 299–305.
14.
MaL, ChenJ, WangR, HanY, ZhangJ, DongW, ZhangX, WuY, ZhaoZ (2015) The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment. J Clin Neurosci22, 649–652.
15.
YounYC, ParkKW, HanSH, KimS (2011) Urine neural thread protein measurements in Alzheimer disease. J Am Med Dir Assoc12, 372–376.
16.
O’BryantSE, MielkeMM, RissmanRA, ListaS, VandersticheleH, ZetterbergH, LewczukP, PosnerH, HallJ, JohnsonL, FongY-L, LuthmanJ, JerominA, Batrla-UtermannR, VillarrealA, BrittonG, SnyderPJ, HenriksenK, GrammasP, GuptaV, MartinsR, HampelH (2017) Perspective: Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement13, 45–58.
17.
ChatterjeeP, GuptaVB, FaganAM, JasielecMS, XiongC, SohrabiHR, DhaliwalS, TaddeiK, BourgeatP, BrownBM, BenzingerT, BatemanRJ, MorrisJC, MartinsRN (2015) Decreased platelet APP isoform ratios in autosomal dominant Alzheimer’s disease: Baseline data from a DIAN cohort subset. Curr Alzheimer Res12, 157–164.
18.
LiuL, ZhangK, TanL, ChenYH, CaoYP (2015) Alterations in cholesterol and ganglioside GM1 content of lipid rafts in platelets from patients with Alzheimer disease. Alzheimer Dis Assoc Disord29, 63–69.
19.
McGuinnessB, FuchsM, BarrettSL, PassmoreAP, JohnstonJA (2016) Platelet membrane beta-secretase activity in mild cognitive impairment and conversion to dementia: A longitudinal study. J Alzheimers Dis49, 1095–1103.
20.
Mukaetova-LadinskaEB, Abdel-AllZ, AndradeJ, Alves da SilvaJ, O’BrienJT, KalariaRN (2015) Plasma and platelet clusterin ratio is altered in Alzheimer’s disease patients with distinct neuropsychiatric symptoms: Findings from a pilot study. Int J Geriatr Psychiatry30, 368–375.
21.
KocER, UzarE, CirakY, Parlak DemirY, IlhanA (2014) The increase of mean platelet volume in patients with Alzheimer disease. Turk J Med Sci44, 1060–1066.
22.
ColciaghiF, MarcelloE, BorroniB, ZimmermannM, CaltagironeC, CattabeniF, PadovaniA, Di LucaM (2004) Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology62, 498–501.
23.
BushAI, MartinsRN, RumbleB, MoirR, FullerS, MilwardE, CurrieJ, AmesD, WeidemannA, FischerP, MulthaupG, BeyreutherK, MastersCL (1990) The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem265, 15977–15983.
24.
EvinG, LiQX (2012) Platelets and Alzheimer’s disease: Potential of APP as a biomarker. World J Psychiatry2, 102–113.
25.
GowertNS, DonnerL, ChatterjeeM, EiseleYS, TowhidST, MunzerP, WalkerB, OgorekI, BorstO, GrandochM, SchallerM, FischerJW, GawazM, WeggenS, LangF, JuckerM, ElversM (2014) Blood platelets in the progression of Alzheimer’s disease. PLoS One9, e90523.
26.
SmithCC (1997) Stimulated release of the beta-amyloid protein of Alzheimer’s disease by normal human platelets. Neurosci Lett235, 157–159.
27.
PlaggB, MarksteinerJ, KniewallnerKM, HumpelC (2015) Platelet dysfunction in hypercholesterolemia mice, two Alzheimer’s disease mouse models and in human patients with Alzheimer’s disease. Biogerontology16, 543–558.
28.
PadovaniA, BorroniB, ColciaghiF, PettenatiC, CottiniE, AgostiC, LenziGL, CaltagironeC, TrabucchiM, CattabeniF, Di LucaM (2002) Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol59, 71–75.
29.
Bermejo-BescosP, Martin-AragonS, Jimenez-AliagaK, BenediJ, FeliciE, GilP, Manuel RiberaJ, Maria VillarA (2013) Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI). Neurochem Res38, 1415–1423.
30.
BorroniB, ColciaghiF, CaltagironeC, RozziniL, BroglioL, CattabeniF, Di LucaM, PadovaniA (2003) Platelet amyloidprecursor protein abnormalities in mild cognitive impairmentpredict conversion to dementia of Alzheimer type: A 2-yearfollow-up study. Arch Neurol60, 1740–1744.
31.
ZainaghiIA, TalibLL, DinizBS, GattazWF, ForlenzaOV (2012) Reduced platelet amyloid precursor protein ratio (APP ratio)predicts conversion from mild cognitive impairment toAlzheimer’s disease. J Neural Transm (Vienna)119, 815–819.
32.
ZainaghiIA, ForlenzaOV, GattazWF (2007) Abnormal APP processing in platelets of patients with Alzheimer’s disease: Correlations with membrane fluidity and cognitive decline. Psychopharmacology (Berl)192, 547–553.
33.
RosenbergRN, BaskinF, FosmireJA, RisserR, AdamsP, SvetlikD, HonigLS, CullumCM, WeinerMF (1997) Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol54, 139–144.
34.
Di LucaM, PastorinoL, CattabeniF, ZanardiR, ScaroneS, RacagniG, SmeraldiE, PerezJ (1996) Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol53, 1162–1166.
35.
BaskinF, RosenbergRN, IyerL, HynanL, CullumCM (2000) Platelet APP isoform ratios correlate with declining cognition in AD. Neurology54, 1907–1909.
36.
BorroniB, ColciaghiF, CorsiniP, AkkawiN, RozziniL, Del ZottoE, TalaricoG, CattabeniF, LenziGL, Di LucaM, PadovaniA (2002) Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms. Neurol Sci23, 207–210.
37.
ColciaghiF, BorroniB, PastorinoL, MarcelloE, ZimmermannM, CattabeniF, PadovaniA, Di LucaM (2002) [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med8, 67–74.
38.
Di LucaM, PastorinoL, BianchettiA, PerezJ, VignoloLA, LenziGL, TrabucchiM, CattabeniF, PadovaniA (1998) Differential level of platelet amyloid beta precursor protein isoforms: An early marker for Alzheimer disease. Arch Neurol55, 1195–1200.
39.
JelicV, HagmanG, YamamotoNG, TeranishiY, NishimuraT, WinbladB, PavlovPF (2013) Abnormal platelet amyloid-β protein precursor (AβPP) metabolism in Alzheimer’s disease: Identification and characterization of a new AβPP isoform as potential biomarker. J Alzheimers Dis35, 285–295.
40.
PadovaniA, PastorinoL, BorroniB, ColciaghiF, RozziniL, MonasteroR, PerezJ, PettenatiC, MussiM, ParrinelloG, CottiniE, LenziGL, TrabucchiM, CattabeniF, Di LucaM (2001) Amyloid precursor protein in platelets: A peripheral marker for the diagnosis of sporadic AD. Neurology57, 2243–2248.
SrisawatC, JunnuS, PeerapittayamongkolC, FutrakulA, Soi-ampornkulR, SenanarongV, PraditsuwanR, AssantachaiP, NeungtonN (2013) The platelet amyloid precursor protein ratio as a diagnostic marker for Alzheimer’s disease in Thai patients. J Clin Neurosci20, 644–648.
43.
ZimmermannM, BorroniB, CattabeniF, PadovaniA, Di LucaM (2005) Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis19, 237–242.
44.
LiuHC, WangHC, KoSY, WangPN, ChiCW, HongCJ, LinKN, LiuTY (2007) Correlation between platelet amyloid precursor protein isoform ratio and cognition in Alzheimer’s disease. J Alzheimers Dis11, 77–84.
45.
LiberatiA, AltmanDG, TetzlaffJ, MulrowC, GotzschePC, IoannidisJP, ClarkeM, DevereauxPJ, KleijnenJ, MoherD (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ339, b2700.
46.
LoCK, MertzD, LoebM (2014) Newcastle-Ottawa Scale: Comparing reviewers’ to authors’ assessments. BMC Med Res Methodol14, 45.
47.
NalivaevaNN, TurnerAJ (2013) The amyloid precursor protein: A biochemical enigma in brain develoment, function and disease. FEBS Lett587, 2046–2054.
48.
SchlossmacherMG, OstaszewskiBL, HeckerLI, CeliA, HaassC, ChinD, LieberburgI, FurieBC, FurieB, SelkoeDJ (1992) Detection of distinct isoform patterns of the beta-amyloid precursor protein in human platelets and lymphocytes. Neurobiol Aging13, 421–434.
BushAI, WhyteS, ThomasLD, WilliamsonTG, Van TiggelenCJ, CurrieJ, SmallDH, MoirRD, LiQX, RumbleB, et al. (1992) An abnormality of plasma amyloid protein precursor in Alzheimer’s disease. Ann Neurol32, 57–65.
52.
TangK, HynanLS, BaskinF, RosenbergRN (2006) Platelet amyloid precursor protein processing: A bio-marker for Alzheimer’s disease. J Neurol Sci240, 53–58.
KozubskiW, SwiderekM, KloszewskaI, GwozdzinskiK, WatalaC (2002) Blood platelet membrane fluidity and the exposition ofmembrane protein receptors in Alzheimer disease (AD)patients–preliminary study. Alzheimer Dis Assoc Disord16, 52–54.
55.
ZubenkoGS, TeplyI, WinwoodE, HuffFJ, MoossyJ, SunderlandT, MartinezAJ (1996) Prospective study of increased platelet membrane fluidity as a risk factor for Alzheimer’s disease: Results at 5 years. Am J Psychiatry153, 420–423.
56.
TamaokaA, FukushimaT, SawamuraN, IshikawaK, OguniE, KomatsuzakiY, ShojiS (1996) Amyloid beta protein in plasma frompatients with sporadic Alzheimer’s disease. J NeurolSci141, 65–68.
57.
SongF, PoljakA, SmytheGA, SachdevP (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer’s disease. Brain Res Rev61, 69–80.
58.
LövheimH, ElghF, JohanssonA, ZetterbergH, BlennowK, HallmansG, ErikssonS (2017) Plasma concentrations of free amyloid β cannot predict the development of Alzheimer’s disease. Alzheimers Dement13, 778–782.
59.
SrisawatC, JunnuS, PeerapittayamongkolC, FutrakulA, Soi-ampornkulR, SenanarongV, PraditsuwanR, AssantachaiP, NeungtonN (2013) The platelet amyloid precursor protein ratio as a diagnostic marker for Alzheimer’s disease in Thai patients. J Clin Neurosci20, 644–648.
